scholarly journals Sex Steroids Affect Triglyceride Handling, Glucose-Dependent Insulinotropic Polypeptide, and Insulin Sensitivity: A 1-week randomized clinical trial in healthy young men

Diabetes Care ◽  
2010 ◽  
Vol 33 (8) ◽  
pp. 1831-1833 ◽  
Author(s):  
B. Lapauw ◽  
M. Ouwens ◽  
L. M. 't Hart ◽  
B. Wuyts ◽  
J. J. Holst ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Insulin Sensitivity ◽  
Randomized Clinical Trial ◽  
Sex Steroids ◽  
Young Men

Effects of myofascial release of the ankle plantar flexors on static postural balance of young men: A randomized clinical trial

2021 ◽  
Vol 28 ◽  
pp. 121-125
Author(s):  
Deise Laurenço Freire Ribeiro ◽  
Flávia V.A. Medeiros ◽  
Emmanuela B.A. Marinho ◽  
João Batista Ferreira Júnior ◽  
Martim F. Bottaro ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Postural Balance ◽  
Young Men ◽  
Plantar Flexors ◽  
Myofascial Release

Response to Comment on “Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women”

Science ◽  
2021 ◽  
Vol 373 (6554) ◽  
pp. eabj7375
Author(s):  
Samuel Klein ◽  
Mihoko Yoshino
Keyword(s):  
Clinical Trial ◽  
Insulin Sensitivity ◽  
Randomized Clinical Trial ◽  
Primary Outcome ◽  
Nicotinamide Mononucleotide ◽  
Triglyceride Content

In evaluating any randomized clinical trial, it is important to determine whether baseline differences between groups could have affected the primary outcome. In our study, muscle insulin sensitivity, which was identical in both groups at baseline, improved after nicotinamide mononucleotide (NMN), not placebo, therapy. Differences in baseline intrahepatic triglyceride content between groups do not negate the effects of NMN observed in muscle.

scholarly journals Effects of Pitavastatin on Insulin Sensitivity and Liver Fat: A Randomized Clinical Trial

2018 ◽  
Vol 103 (11) ◽  
pp. 4176-4186 ◽  
Author(s):  
Laurie R Braun ◽  
Meghan N Feldpausch ◽  
Natalia Czerwonka ◽  
Julian Weiss ◽  
Karen Branch ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Insulin Sensitivity ◽  
Randomized Clinical Trial ◽  
Liver Fat

scholarly journals Selenium supplementation and insulin resistance in a randomized, clinical trial

2019 ◽  
Vol 7 (1) ◽  
pp. e000613 ◽  
Author(s):  
Elizabeth Theresa Jacobs ◽  
Peter Lance ◽  
Lawrence J Mandarino ◽  
Nathan A Ellis ◽  
H-H Sherry Chow ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Insulin Sensitivity ◽  
Randomized Clinical Trial ◽  
Cell Function ◽  
Controlled Trial ◽  
Fasting Blood Glucose ◽  
Oral Glucose ◽  
Model Assessment ◽  
Β Cell ◽  
Β Cell Function

ObjectiveWhile controversial, observational and randomized clinical trial data implicate the micronutrient selenium (Se) in the development of type 2 diabetes (T2D). The aim of this study was to test the hypothesis that Se supplementation adversely affects pancreatic β-cell function and insulin sensitivity.Research design and methodsIn a subset of 400 individuals participating in a randomized, placebo-controlled trial of Se at 200 µg/day for colorectal adenomatous polyps, fasting plasma glucose and insulin were measured before randomization and within 6 months of completing intervention. Change in the homeostasis model assessment-β cell function (HOMA2-%β) and insulin sensitivity (HOMA2-%S) were compared between arms. A subgroup of 175 (79 Se and 96 placebo) participants underwent a modified oral glucose tolerance test (mOGTT) at the end of intervention and change in glucose values was assessed.ResultsNo statistically significant differences were observed for changes in HOMA2-%β or HOMA2-%S between those who received Se compared with placebo. After a mean of 2.9 years on study, mean HOMA2-%β values were 3.1±24.0 and 3.1±29.8 for the Se and placebo groups, respectively (p=0.99). For HOMA2-%S, the values were −0.5±223.2 and 80.9±1530.9 for the Se and placebo groups, respectively (p=1.00). Stratification by sex or age did not reveal any statistically significant effects on insulin sensitivity by treatment group. For mOGTT, mean baseline fasting blood glucose concentrations were significantly higher among participants in the placebo group compared with the Se group (96.6±14.6 and 92.3±12.0, respectively; p=0.04), a trend which remained through the 20 min assessment.ConclusionsThese findings do not support a significant adverse effect of daily Se supplementation with 200 µg/day of selenized yeast on β-cell function or insulin sensitivity as an explanation for previously reported associations between Se and T2D. Further clarification of longer term effects of Se is needed.Clinical trial registryNIH Clinical Trials.gov numberNCT00078897.

Sign in / Sign up

Export Citation Format

Share Document